Discovery of drug mode of action and drug repositioning from transcriptional responses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 33, 2010, Pages 14621-14626

  Iorio, Francesco ^a,d   Bosotti, Roberta ^b   Scacheri, Emanuela ^b   Belcastro, Vincenzo ^a   Mithbaokar, Pratibha ^a   Ferriero, Rosa ^a   Murino, Loredana ^d   Tagliaferri, Roberto ^d   Brunetti Pierri, Nicola ^a,c   Isacchi, Antonella ^b   Di Bernardo, Diego ^a,c  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b Nerviano Medical Sciences ^*  (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Chemotherapy; Computational drug discovery; Drug repurposing; Systems biology

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2 INHIBITOR; DNA TOPOISOMERASE INHIBITOR; FASUDIL; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; CAMPTOTHECIN; DOXORUBICIN; DRUG DERIVATIVE; FLAVONOID; FLAVOPIRIDOL; IRINOTECAN; N (6,6 DIMETHYL 5 ((1 METHYLPIPERIDIN 4 YL)CARBONYL) 1,4,5,6 TETRAHYDROPYRROLO(3,4 C)PYRAZOL 3 YL) 3 METHYLBUTANAMIDE; N-(6,6-DIMETHYL-5-((1-METHYLPIPERIDIN-4-YL)CARBONYL)-1,4,5,6-TETRAHYDROPYRROLO(3,4-C)PYRAZOL-3-YL)-3-METHYLBUTANAMIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; RNA POLYMERASE II;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PHARMACOGENETICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THEORY; ALGORITHM; CLASSIFICATION; DNA MICROARRAY; DRUG DEVELOPMENT; DRUG SCREENING; FUZZY LOGIC; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ALGORITHMS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE, TUMOR; DOXORUBICIN; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; FUZZY LOGIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PIPERIDINES; PYRAZOLES; PYRROLES; RNA POLYMERASE II;

EID: 77957044703     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1000138107     Document Type: Article

References (47)

1. Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G (2007) Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 6:891-903.
2. di Bernardo D, et al. (2005) Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat Biotechnol 23:377-383.
3. Ambesi-Impiombato A, di Bernardo D (2006) Computational biology and drug discovery: From single-tTarget to network drugs. Curr Bioinform 1:3-13.
4. Berger SI, Iyengar R (2009) Network analyses in systems pharmacology. Bioinformatics 25:2466-2472.
5. Hopkins AL (2008) Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 4:682-690.
6. Mani KM, et al. (2008) A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol 4:169.
7. Gardner TS, di Bernardo D, Lorenz D, Collins JJ (2003) Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301:102-105.
8. Hu G, Agarwal P (2009) Human disease-drug network based on genomic expression profiles. PloS One 4(8):e6536.
9. Hughes TR, et al. (2000) Functional discovery via a compendium of expression profiles. Cell 102(1):109-126.
10. Kohanski MA, Dwyer DJ, Wierzbowski J, Cottarel G, Collins JJ (2008) Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell 135(4):679-690.
11. Lamb J (2007) The Connectivity Map: A new tool for biomedical research. Nat Rev Cancer 7(1):54-60.
12. Lamb J, et al. (2006) The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935.
13. Yang K, Bai H, Ouyang Q, Lai L, Tang C (2008) Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 4:228.
14. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321:263-266.
15. Li J, Zhu X, Chen JY (2009) Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput Biol 5 (7):e1000450.
16. Keiser MJ, et al. (2009) Predicting new molecular targets for known drugs. Nature 462:175-181.
17. Miller MA (2002) Chemical database techniques in drug discovery. Nat Rev Drug Discov 1:220-227.
18. Iorio F, Tagliaferri R, di Bernardo D (2009) Identifying network of drug mode of action by gene expression profiling. J Comput Biol 16:241-251.
19. McAuley JJ, Costa LF, Caetano TS (2007) Rich-club phenomenon across complex network hierarchy. Appl Phys Lett 91:084103.
20. Diaconis P, Graham R (1977) Spearman's footrule as a measure of disarray. J R Stat Soc 39:262-268.
21. Lin S, et al. (2010) Space oriented rank-based data integration. Stat Appl Genet Mol Biol 9:Article20.
22. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550.
23. Frey BJ, Dueck D (2007) Clustering by passing messages between data points. Science 315:972-976.
24. Newman ME (2006) Modularity and community structure in networks. Proc Natl Acad Sci USA 103:8577-8582.
25. Pahor M, et al. (1994) Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10(4):405-411.
26. Schwabe U (1995) ATC-Code (Wissenschaftliches Institut der AOK, Bonn, Germany).
27. Wishart DS (2008) DrugBank and its relevance to pharmacogenomics. Pharmacogenomics 9:1155-1162.
28. Seiler KP, et al. (2008) ChemBank: A small-molecule screening and cheminformatics resource database. Nucleic Acids Res 36(Database issue):D351-359.
29. Eccles SA, et al. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68:2850-2860.
30. Fogliatto G, et al. (2009) Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy. American Association for Cancer Research - Annual Meeting Poster 37 (Abstract #4685).
31. Yang Q, et al. (2005) Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci USA 102:9631-9636.
32. Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30:630-641.
33. Senderowicz AM (1999) Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17:313-320.
34. Brasca MG, et al. (2009) Identification of N,1,4,4-tetramethyl-8-{[4-(4- methylpiperazin-1-yl)phenyl]amino}-4,5-dihydr o-1H-pyrazolo[4,3-h]quinazoline-3- carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 52:5152-5163.
35. Abal M, et al. (2004) Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 23:1737-1744.
36. Liu W, Zhang R (1998) Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol 12:793-804.
37. Amente S, Gargano B, Napolitano G, Lania L, Majello B (2009) Camptothecin releases P-TEFb from the inactive 7SK snRNP complex. Cell Cycle 8:1249-1255.
38. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ (2007) Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6:304-312.
39. Ravikumar B, et al. (2003) Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum Mol Genet 12:985-994.
40. de Medina P, Silvente-Poirot S, Poirot M (2009) Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 5:1066-1067.
41. Criollo A, et al. (2007) Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ 14:1029-1039. (Pubitemid 46629841)
42. Lei X, et al. (2006) Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 20:2147-2149.
43. Ogata M, et al. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26:9220-9231.
44. Mizushima N (2004) Methods for monitoring autophagy. Int J Biochem Cell Biol 36:2491-2502.
45. Cvek B, Dvorak Z (2008) The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 13:716-722.
46. Yang H, Shi G, Dou QP (2007) The tumor proteasome is a primary target for the natural anticancercompound Withaferin A isolated from "Indian winter cherry". Mol Pharmacol 71:426-437.
47. Hehner SP, Hofmann TG, Droge W, Schmitz ML (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163:5617-5623.